Resource utilization in asthma: Combined fluticasone propionate/salmeterol compared with inhaled corticosteroids

Current Medical Research and Opinion

Volumn 23, Issue 2, 2007, Pages 427-434

  Friedman, Howard S ^a   Yawn, Barbara P ^b  

^a Analytic Solutions LLC   (United States)

^b OLMSTED MEDICAL CENTER   (United States)

Author keywords

Asthma; Costs; Inhaled corticosteroid; Long acting 2 agonist; Resources

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CONTROLLED STUDY; DRUG COST; FEMALE; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRACTICE GUIDELINE; SCHOOL CHILD;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; COMORBIDITY; DRUG COSTS; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; OFFICE VISITS; PATIENT ACCEPTANCE OF HEALTH CARE; PRACTICE GUIDELINES; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 33847342587     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X167417     Document Type: Article

References (24)

1. National Center for Health Statistics. Asthma prevalence, health care use and mortality, 2002. Available at: http://www. cdc.gov/nchs/products/pubs/pubd/ hestats/asthma/asthma.htm [last accessed 2006 January 30]
2. Anon. Chartbook on cardiovascular, lung, and blood diseases, 2004. Available at: http://www.nhlbi.nih.gov/resources/ docs/04_chtbk.pdf [last accessed 2006 April 13]
3. Yawn BP, Fryer GE, Phillips RL, et al. Using the ecology model to describe the impact of asthma on patterns of health care. BMC Pulm Med 2005;5:7
4. Cisternas MG, Blanc PD, Yen IH, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol 2003;111:1212-8
5. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164:1392-7
6. Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003;361:1071-6
7. National Asthma Education and Prevention Program (NAEPP). Guidelines for the diagnosis and management of asthma update on selected topics 2002. Bethesda (MD): National Heart, Lung, and Blood Institute; 2003 [Report No.: NIH Publication No. 02-5074]
8. Minnesota Department of Human Services. Judicious use of Advair, 2005. Available at: http://www.dhs.state.mn.us/main/groups/business_partners/ documents/pub/dhs_id_053529.pdf [last accessed 2005 November 21]
9. Ni-Chroinin M, Greenstone IR, Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults. Cochrane Database Syst Rev 2005;CD005307
10. Campbell DA, Robinson DS. Cost advantages of combination asthma therapy. Treat Respir Med 2004;3:133-7
11. Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000;105:1108-16
12. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? [The Gaining Optimal Asthma ControL study]. Am J Respir Crit Care Med 2004;170:836-44
13. Strand AM, Luckow A. Initiation of maintenance treatment of persistent asthma: salmeterol/fluticasone propionate combination treatment is more effective than inhaled steroid alone. Respir Med 2004;98:1008-15
14. O'Connor RD, Nelson H, Borker R, et al. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. Pharmacoeconomics 2004;22:815-25
15. Stempel DA, Riedel AA, Carranza Rosenzweig JR. Resource utilization with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies in children with asthma. Curr Med Res Opin 2006;22:463-70
16. LeNoir M, Williamson A, Stanford RH, Stempel DA. Assessment of asthma control in a general population of asthmatics. Curr Med Res Opin 2006;22:17-22
17. Colice G, Wu EQ, Birnbaum H, et al. Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population. J Occup Environ Med 2006;48:794-802
18. Allen-Ramey FC, Bukstein D, Luskin A, et al. Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy. J Managed Care Pharm 2006;12:310-21
19. Rosenbaum P, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
20. Brookhart MA, Schneeweiss S, Rothman KJ, et al. Variable selection for propensity score models. Am J Epidemiol 2006;163:1149-56
21. Stempel DA, Mauskopf J, McLaughlin T, et al. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med 2001;95:227-34
22. Piecoro LT, Potoski M, Talbert JC, Doherty DE. Asthma prevalence, cost, and adherence with expert guidelines on the utilization of health care services and costs in a state Medicaid population. Health Serv Res 2001;36:357-71
23. Doerschug KC, Peterson MW, Dayton CS, Kline JN. Asthma guidelines: an assessment of physician understanding and practice. Am J Respir Crit Care Med 1999;159:1735-41
24. US Food and Drug Administration. Serevent diskus, advair diskus, and foradil information (long acting beta agonists), 2006 Available at: http://www.fda.gov/cder/drug/infopage/LABA/default.htm [last accessed 2006 April 13]